Preliminary assessing no-surgical treatment response in bronchogenic carcinoma with double-phase contrast material-enhanced computed tomography

Objective： To evaluate the efficacy of double-phase contrast material-enhanced computed tomography （CT） in assessing no-surgical treatment response in bronchogenic carcinoma preliminarily. Methods： 52 patients with bronchogenic carcinoma after no-surgical treatment underwent double-phase contrast material-enhanced computed tomography. Two spiral CT scans were obtained at 25 and 90 seconds respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 4 mUs by using an autoinjector. Precontrast and postcontrast attenuation on every scan was recorded and peak height was calculated. Enhancement pattern was evaluated on the images obtained at 25 and 90 seconds after injection of contrast medium. Results： Precontrast attenuation, postcontrast attenuation at 25 and 90 seconds were 42.20 ± 7.43 Hu, 57.35 ± 10.09 Hu and 71.85 ±12.45 Hu, respectively. No statistically significant difference in precontrast attenuation was found between our results in the study and the results in our old study （mean precontrast attenuation 40.70 Hu） which was obtained in cases before therapy （t = 1.455, P = 0.152 〉 0.05）. Peak height of bronchogenic carcinoma after no-surgical treatment （29.46 ±10.85 Hu） were significantly lower than that of bronchogenic carcinoma before therapy obtained in our old study （mean peak height 35.79 Hu; t = 4.206, P = 0.001 〈 0.05）. 32 of 52 cases showed homogeneous enhancement at 90 seconds. Of the 32 cases, there were 21 with inhomogeneous enhancement, 7 with inhomogeneous enhancement, 2 with central enhancement and 2 with peripheral enhancement at 25 seconds. Conclusion： Bronchogenic carcinoma after no-surgical treatment shows a gradual increase to the peak height after administration of contrast material. Peak heights can reflect the blood supply of bronchogenic carcinoma and might be index for evaluation of no-surgical treatment response in bronchogenic carcinoma.

Study of serum level of sex hormones and expression of their receptors in patients with bronchogenic carcinoma

Objective: To study the serum level of estradiol, progesterone and testosterone (SEL, SPL and STL) and the expression of the receptors of estradiol and progesterone (ER and PR) in 53 cases of bronchogenic carcinoma. Methods: ER and PR in the tissue of the carcinoma were determined with enzyme-linked affinity histochemical method. SEL, SPL and STL were measured with double antibody radioimmunoassay. Results: Most of ER and PR were present in the cytoplasm of the malignant cells (58.2%) and the positive rates of ER and PR were 49.1% and 54.7% respectively. SEL and SPL were significantly higher in the patients with lung cancer than in the subjects of the control groups (P<0.05), no matter whether ER and PR were positive or negative. SEL and SPL were lower in the ER positive, PR positive and both ER and PR positive groups than in the ER negative, PR negative and both ER and PR negative groups. Conclusion: The existence of ER and PR in the patients with bronchogenic carcinoma indicates that the pathogenesis of bronchogenic carcinoma is sex hormone dependent to some extent. ER and SEL are negatively correlated with a correlative coefficient of -1.

Imaging diagnosis of bronchogenic carcinoma(the forgotten disease)during times of COVID-19 pandemic:Current and future perspectives

Patients with bronchogenic carcinoma comprise a high-risk group for coronavirus disease 2019(COVID-19),pneumonia and related complications.Symptoms of COVID-19 related pulmonary syndrome may be similar to deteriorating symptoms encountered during bronchogenic carcinoma progression.These resemblances add further complexity for imaging assessment of bronchogenic carcinoma.Similarities between clinical and imaging findings can pose a major challenge to clinicians in distinguishing COVID-19 super-infection from evolving bronchogenic carcinoma,as the above-mentioned entities require very different therapeutic approaches.However,the goal of bronchogenic carcinoma management during the pandemic is to minimize the risk of exposing patients to COVID-19,whilst still managing all life-threatening events related to bronchogenic carcinoma.The current pandemic has forced all healthcare stakeholders to prioritize per value resources and reorganize therapeutic strategies for timely management of patients with COVID-19 related pulmonary syndrome.Processing of radiographic and computed tomography images by means of artificial intelligence techniques can facilitate triage of patients.Modified and newer therapeutic strategies for patients with bronchogenic carcinoma have been adopted by oncologists around the world for providing uncompromised care within the accepted standards and new guidelines.

Assessing no-surgical treatment response in bronchogenic carcinoma with contrast material-enhanced computed tomography

Objective:The aim of the study was to evaluate the efficacy of contrast material-enhanced computed tomography(CT) in assessing no-surgical treatment response in bronchogenic carcinoma.Methods:The 67 patients with bronchogenic carcinoma after no-surgical treatment underwent two-phase contrast material-enhanced computed tomography.Two spiral CT scans were obtained at 25 and 90 s respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 4 mL/s by using an autoinjector.Precontrast and postcontrast attenuation values on every scan were recorded and peak height was calculated.Enhancement pattern was evaluated on the image obtained at 25 and 90 s after injection of contrast medium.Results:Precontrast attenuation value,postcontrast attenuation values at 25 and 90 s were(41.26 ± 7.77) Hu,(56.45 ± 10.48) Hu,(70.82 ± 11.99) Hu,respectively.No statistically significant difference in precontrast attenuation was found between our results in this study and the results in our old study(mean precontrast attenuation 40.70 Hu) which was obtained in cases without any therapy(t = 0.593,P = 0.555﹥0.05).Peak height of bronchogenic carcinoma after no-surgical treatment [(29.40 ± 10.73) Hu] were significantly lower than that of bronchogenic carcinoma without any therapy obtained in our old study(mean peak height 35.79 Hu)(t =-4.874,P = 0.001 < 0.05).The 39 among 67 cases appeared homogeneous enhancement at 90 s.At 25 s,there were 26 cases with inhomogeneous enhancement,9 cases with homogeneous enhancement,2 cases with central enhancement,and 2 cases with peripheral enhancement among the 39 cases.Conclusion:Peak heights can reflect the blood supply of bronchogenic carcinoma and might be an index for evaluation of no-surgical treatment response in bronchogenic carcinoma.

Preliminary assessing no-surgical treatment response in bronchogenic carcinoma with three-phase contrast material-enhanced MRI

Objective:The aim of this study was to evaluate the efficacy of three-phase contrast material-enhanced MRI in assessing no-surgical treatment response in peripheral bronchogenic carcinoma preliminarily.Methods:Twenty-two patients with bronchogenic carcinoma after no-surgical treatment underwent three-phase contrast material-enhanced MRI.Three scans were obtained at 25 s,120 s and 180 s respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 2 mL/s by using an autoinjector.Precontrast and postcontrast signal intensity on every scan was recorded.Peak Height(PH) and Maximum Enhancement(Emax) were calculated.Enhancement pattern was evaluated on the images obtained at 120 s and 180 s after injection of contrast medium.Results:Precontrast signal intensity,postcontrast signal intensity at 120 s and 180 s were 478 ± 108,926 ± 209 and 1050 ± 252.PH(571 ± 225) and Emax(119 ± 49) of bronchogenic carcinoma after no-surgical treatment were significantly lower than those of bronchogenic carcinoma without any therapy(mean PH 655,mean Emax 150)(t = 2.178,P = 0.005 < 0.05,t = 4.196,P = 0.001 < 0.05).Six cases among 22 appeared homogeneous enhancement at 180 s.At 120 s,there were 4 cases with inhomogeneous enhancement,1 case with homogeneous enhancement,1 case with peripheral enhancement among the 6 cases.Conclusion:Bronchogenic carcinoma after no-surgical treatment shows a gradual increase to the PH after administration of contrast material.Three-phase contrast material-enhanced MRI can reflect the blood supply of bronchogenic carcinoma and might be effective approach for evaluation of no-surgical treatment response in bronchogenic carcinoma.

Peripheral bronchogenic carcinoma: Enhancement pattern evaluation on PACS and CT workstations

Objective: The aim of the study was to determine the efficiency and effectiveness of picture archiving and communication system(PACS) workstation in detecting enhancement pattern of peripheral bronchogenic carcinoma. Methods: The 62 patients with peripheral bronchogenic carcinoma underwent two-phase contrast material-enhanced multislices computed tomography(MSCT) of the chest in a single-breath-hold technique. Two spiral CT scans were obtained at 25 s and 90 s respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 4 m L/s by using an autoinjector. Precontrast and postcontrast attenuation on every scan were measured on PACS and CT workstations respectively and peak height was calculated. Enhancement pattern was evaluated on the image obtained at 90 s after injection of contrast medium on PACS and CT workstations respectively. Results: No statistically significant difference in precontrast attenuation, postcontrast attenuation at 25 s and 90 s was found between these measured on a PACS workstation [(40.21 ± 7.03) HU;(55.53 ± 11.09) HU;(75.95 ± 13.45) HU] and those [(39.01 ± 8.95) HU;(56.01 ± 10.91) HU;(76.03 ± 11.95) HU] on a CT workstation(t = 1.140, P = 0.256 > 0.05; t = 1.580, P = 0.149 > 0.05; t = 1.505, P = 0.150﹥0.05). The peak height that calculated on a PACS workstation was 35.74 HU(20 HU). There was not statistically significant difference in peak height between that calculated on a PACS workstation and that on a CT workstation [(37.02 ± 12.05) HU; t = 2.001, P = 0.099 > 0.05]. The tumors showed same enhancement pattern on PACS workstation and CT workstation. Of the 62 cases, 38 showed homogeneous enhancement, 17 showed heterogeneous enhancement, five showed peripheral enhancement, two showed central enhancement, at 90 s. The enhancement pattern revealed on PACS workstation was consistent with feature of peripheral bronchogenic carcinoma. Conclusion: The efficiency and effectiveness of PACS workstation is as same as those of CT workstation in detecting enhancement pattern of peripheral bronchogenic carcinoma.

Bronchogenic Carcinoma in a Scleroderma Patient with Multiple Metastases： One Case Report

IntroductionThe association between pulmonary interstitial fibrosis and the development of bronchogenic carcinoma in a patient with scleroderma has been reported rarely. It is hypothesized that intense epithelial proliferation that is accompanied by the .brotic process increases the occurrence of carcinomatous changes. We report the case of a pa-tient who presented with 3-year history of Raynaud＇s phenomenon, gradual tightening of the skin which was ignored by the patient and her family members, and a 2-week history of severe respiratory dis-tress with left shoulder and upper back pain followed by the develop-ment of paraparesis. After a series of examinations, the patient was diagnosed with scleroderma and simultaneously with bronchogenic carcinoma and multiple distant metastases.

Surgical results and prognosis of patients with primary bronchogenic carcinoma aged less than 30 years

Objective To investigate and analyze the clinical and pathological features of surgical treatment for primary bronchogenic carcinoma in adolescent patients. Methods A retrospective review is presented of patients less than 30 years with surgical treatment of bronchogenic

DETECTION OF HUMAN PAPILLOMAVIRUS TYPES 16, 18 DNA RELATED SEQUENCES IN BRONCHOGENIC CARCINOMA BY POLYMERASE CHAIN REACTION

In studying the relationship between human papillomavirus (HPV) and bronchogenic carcinoma, 'high-risk' HPV 16, 18 DNA sequences were detected in samples from 50 lung cancer patients, 18 patients with benign pulmonary diseases and 4 fetal lung tissues by polymerase chain reaction (PCR) and dot-blot hybridization with biotin-labelled probes. The results showed that HPV 16, 18 DNA related sequences were found in 32% of lung cancer specimens, with 10 cases of HPV 16, 5 cases of HPV 18 and 1 case of both types. 48.15% (13 / 27) of squamous cell carcinomas were shown to be positive for HPV 16, 18 DNA. In addition, two adenocarcinomas and one small cell carcinoma were positive for HPV 16 DNA. No specimens from benign diseases tissues and fetal lung tissues showed positive results. These results suggest that primary bronchogenic carcinoma is related to HPV infection.

The anesthesia analysis of the conversion video-assisted thoracic surgery to thoracotomy in pulmonary carcinoma

Objective： The aim of this study was to anesthesia analyse the factors of conversing video-assisted thoracic surgery to thoracectomy in pulmonary carcinoma. Methods： Double-lumen tube bronchial catheter intubation and interstitial positive pressure ventilation （IPPV） were used in all patients with video-assisted thoracic surgery after fast-speed venous induced anesthesia. IPPV, positive expiratory pressure （PEEP） and continuous positive airway pressure （CPAP） in collapse lobes of lung were used in one lung ventilation, and ventilation parameters were adjusted. Results： Two hundred and fifity- two patients double-lumen bronchial tube intubation used by fiberscope was located very well. The level of oxygen saturation of blood （Sp02）, end.tidal carbon dioxide pressure （PETCO2） could be maintained normal. 5 cases were forced to converse video-assisted thoracic surgery to thoracotomy because of 2 cases pulmonary adhesion, 2 cases severe pulmonary dysfunction and 1 case abnormal anatomy respectively. Conclusion： Long one lung ventilation such as pulmonary adhesion, severe pulmonary dysfunction and abnormal anatomy should be considered to be relative contraindication.